China National Drug Administration grants rapid approval of Roche ’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer

Roche today announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa ® (alectinib) as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news